Verici Logo

Company announcements

  • Register for news alerts from Verici Dx

  • This field is for validation purposes and should be left unchanged.

Company announcements


 

Material Transfer Agreement secured to assess CTOT-19 samples using Clarava™ and Tuteva™

April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has entered into a Material Transfer Agreement (“MTA”) with the Icahn School of Medicine at Mount Sinai and Principal Investigator Dr. Peter Heeger, to allow access to samples from the CTOT-19 (Clinical Trials in Organ Transplant1) trial in an […]
Keep Reading

Final Results for the period ended 31 December 2020

April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its inaugural audited results for the period ended 31 December 2020.   Strategic and Operational highlights Verici Dx was successfully admitted to AIM in November raising gross proceeds of c.$18.8m (£14.5m) The fundraising was significantly oversubscribed by institutional and other […]
Keep Reading

First clinical trial sites initiated in US

March 2, 2021
Three leading US centres first to collaborate with Verici in clinical validation trial for lead products Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has partnered with Lorenzo Gallon, MD, at Northwestern University Feinberg School of Medicine; Milagros Samaniego, MD, at Henry Ford Health System and […]
Keep Reading

Additional patent licence with Mount Sinai

January 11, 2021
Worldwide exclusive licence to liquid biopsy IP for predicting risk of fibrosis and chronic damage rejection Strengthens patent portfolio covering the entire kidney transplant diagnostic pathway   Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has expanded the scope of its licence agreement with the Icahn […]
Keep Reading

Appointment of Senior Director of Clinical Trial Operations Preparatory phase for validation trials complete

December 23, 2020
23 December 2020 Verici Dx plc (“Verici Dx” or the “Company”) Appointment of Senior Director of Clinical Trial Operations Preparatory phase for validation trials complete Site initiation of transplant centres on track for January 2021 Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has appointed Angela […]
Keep Reading

TR-1: Standard form for notification of major holdings

November 13, 2020
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: VERICI DX 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an […]
Keep Reading

TR-1: Standard form for notification of major holdings

November 13, 2020
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: VERICI DX 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an […]
Keep Reading

TR-1: Standard form for notification of major holdings

November 5, 2020
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:             Verici DX Plc 1b. Please indicate if the issuer is a non-UK issuer (please mark […]
Keep Reading

Admission to trading on AIM & First Day of Dealings

November 3, 2020
Capitalised terms used in this announcement shall, unless the context provides otherwise, have the same meaning as defined in the Admission Document. Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that admission to trading on AIM ("Admission") will take place and dealings will commence at 8.00 a.m. today […]
Keep Reading

Successful Restricted Offer Update on Fundraising and Admission

October 30, 2020
Capitalised terms in this announcement carry the same definitions as in prior announcements in relation to the Fundraising.   Verici Dx plc, a developer of advanced clinical diagnostics for organ transplant, announces the result of the Restricted Offer made to its shareholders, who returned a valid application form to subscribe for Verici Dx Ordinary Shares […]
Keep Reading
crossmenu